ASCO Archives

Critical Updates in Kidney, Prostate, Bladder Cancer- ASCO 2023

Critical Updates in Kidney, Prostate, and Bladder Cancer from ASCO 2023 with Dr. Toni Choueiri

July 6, 2023 No Comments

Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School – Dana-Farber Cancer Institute.

Covering four important studies:

– TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations

– CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab vs sunitinib in pts with advanced renal cell carcinoma

– CONTACT-03: efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior checkpoint inhibitor in metastatic renal cell carcinoma

– THOR: Erdafitinib vs chemo in pts with advanced or metastatic urothelial cancer with select FGFR alteration

GI Cancer ASCO 2023 Highlights with Dr. Muhammad Shaalan Beg

June 29, 2023 No Comments

Discussing GI (Gastrointestinal) Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Muhammad Shaalan Beg, Co-Leader Gastrointestinal Oncology, Adjunct Associate Professor of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center. Covering three important studies:

– PROSPECT: ph III trial of neoad chemoRT vs neoadj FOLFOX chemo with selective use of chemoRT, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)

– NORPACT-1: Short-course neoadj FOLFIRINOX vs upfront surgery for resectable pancreatic head cancer

– NAPOLI 3: ph III trial in mets pancreatic ductal adenocarcinoma pts, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) vs nab-paclitaxel + gemcitabine

– IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) from the phase III IMbrave050 trial of adj atezo + bev vs active surveillance in pts with HCC

Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

June 22, 2023 No Comments

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies:

– ADAURA trial update with increase OS with adjuvant Osimertinib

– KEYNOTE 789 – Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant

– KEYNOTE 671 – Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

Breast Cancer ASCO 2023 Highlights with Dr. Stephanie Graff

June 15, 2023 No Comments

Discussing Breast Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies:

– NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients

– SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients

– X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer

GU ASCO 2023 Highlights with Dr. Petros Grivas

February 22, 2023 No Comments

Discussing GU ASCO 2023 Highlights – practice changing / informing studies with Dr. Petros Grivas, Clinical Director of Genitourinary Cancer Program, Professor, Division of Medical Oncology at Fred Hutch Cancer Center.

GI ASCO 2023 Highlights with Dr. Mark Lewis

January 26, 2023 No Comments

Discussing GI ASCO 2023 Highlights – practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare.

SPOTLIGHT – Zolbetuximab with mFOLFOX6 Meets Primary Endpoint
NAPOLI3 – Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer
MOUNTAINEER – FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
SUNLIGHT – Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer